Figure 1From: A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy Patient disposition. *Did not satisfy study inclusion and exclusion criteria. †Abdominal pain secondary to partial small bowel obstruction (later classified as a serious AE, requiring hospitalization). ‡Values did not meet the exclusion criteria; however, the investigator chose to withdraw the patient for safety reasons.Back to article page